Moderna jumps 14% as first mRNA cancer vaccine passes Phase 3 melanoma trial; data wins presidential symposium slot

Moderna shares rose over 14% after its mRNA cancer vaccine became the first to pass a Phase 3 trial, with late-stage melanoma data selected for a presidential symposium slot. The result was first announced on August 19. Merck and BioNTech shares also edged higher.

Detected & updated continuously · Source: Nebula